Synthesis and characterization of Pt(iv) fluorescein conjugates to investigate Pt(iv) intracellular transformations

Ying Song; Kogularamanan Suntharalingam; Jessica S. Yeung; Maksim Royzen; Stephen J. Lippard

doi:10.1021/bc400281a

Synthesis and characterization of Pt(iv) fluorescein conjugates to investigate Pt(iv) intracellular transformations

Ying Song, Kogularamanan Suntharalingam, Jessica S. Yeung, Maksim Royzen, Stephen J. Lippard^*

^*Corresponding author for this work

Chemistry

Massachusetts Institute of Technology

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Abstract

Pt(IV) anticancer compounds typically operate as prodrugs that are reduced in the hypoxic environment of cancer cells, losing two axial ligands in the process to generate active Pt(II) species. Here we report the synthesis of two fluorescent Pt(IV) prodrugs of cisplatin in order to image and evaluate the Pt(IV) reduction process in simulated and real biological environments. Treatment of the complexes dissolved in PBS buffer with reducing agents typically encountered in cells, glutathione or ascorbate, afforded a 3- to 5-fold fluorescence turn-on owing to reduction and loss of their fluorescein-based axial ligands, which are quenched when bound to platinum. Both Pt(IV) conjugates displayed moderate cytotoxicity against human cancer cell lines, with IC₅₀ values higher than that of cisplatin. Immunoblotting and DNA flow cytometry analyses of one of the complexes, Pt(IV)FL₂, revealed that it damages DNA, causes cell cycle arrest in S or G2/M depending on exposure time, and ultimately triggers apoptotic cell death. Fluorescence microscopic studies prove that Pt(IV)FL₂ enters cells intact and undergoes reduction intracellularly. The results are best interpreted in terms of a model in which the axial fluorescein ligands are expelled through lysosomes, with the platinum(II) moiety generated in the process binding to genomic DNA, which results in cell death.

Original language	English
Pages (from-to)	1733-1740
Number of pages	8
Journal	Bioconjugate Chemistry
Volume	24
Issue number	10
DOIs	https://doi.org/10.1021/bc400281a
Publication status	Published - 16 Oct 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/bc400281a

Cite this

@article{669f8a9828624c65a94cdee320379c52,

title = "Synthesis and characterization of Pt(iv) fluorescein conjugates to investigate Pt(iv) intracellular transformations",

abstract = "Pt(IV) anticancer compounds typically operate as prodrugs that are reduced in the hypoxic environment of cancer cells, losing two axial ligands in the process to generate active Pt(II) species. Here we report the synthesis of two fluorescent Pt(IV) prodrugs of cisplatin in order to image and evaluate the Pt(IV) reduction process in simulated and real biological environments. Treatment of the complexes dissolved in PBS buffer with reducing agents typically encountered in cells, glutathione or ascorbate, afforded a 3- to 5-fold fluorescence turn-on owing to reduction and loss of their fluorescein-based axial ligands, which are quenched when bound to platinum. Both Pt(IV) conjugates displayed moderate cytotoxicity against human cancer cell lines, with IC50 values higher than that of cisplatin. Immunoblotting and DNA flow cytometry analyses of one of the complexes, Pt(IV)FL2, revealed that it damages DNA, causes cell cycle arrest in S or G2/M depending on exposure time, and ultimately triggers apoptotic cell death. Fluorescence microscopic studies prove that Pt(IV)FL2 enters cells intact and undergoes reduction intracellularly. The results are best interpreted in terms of a model in which the axial fluorescein ligands are expelled through lysosomes, with the platinum(II) moiety generated in the process binding to genomic DNA, which results in cell death.",

author = "Ying Song and Kogularamanan Suntharalingam and Yeung, {Jessica S.} and Maksim Royzen and Lippard, {Stephen J.}",

year = "2013",

month = oct,

day = "16",

doi = "10.1021/bc400281a",

language = "English",

volume = "24",

pages = "1733--1740",

journal = "Bioconjugate Chemistry",

issn = "1043-1802",

publisher = "American Chemical Society",

number = "10",

}

TY - JOUR

T1 - Synthesis and characterization of Pt(iv) fluorescein conjugates to investigate Pt(iv) intracellular transformations

AU - Song, Ying

AU - Suntharalingam, Kogularamanan

AU - Yeung, Jessica S.

AU - Royzen, Maksim

AU - Lippard, Stephen J.

PY - 2013/10/16

Y1 - 2013/10/16

N2 - Pt(IV) anticancer compounds typically operate as prodrugs that are reduced in the hypoxic environment of cancer cells, losing two axial ligands in the process to generate active Pt(II) species. Here we report the synthesis of two fluorescent Pt(IV) prodrugs of cisplatin in order to image and evaluate the Pt(IV) reduction process in simulated and real biological environments. Treatment of the complexes dissolved in PBS buffer with reducing agents typically encountered in cells, glutathione or ascorbate, afforded a 3- to 5-fold fluorescence turn-on owing to reduction and loss of their fluorescein-based axial ligands, which are quenched when bound to platinum. Both Pt(IV) conjugates displayed moderate cytotoxicity against human cancer cell lines, with IC50 values higher than that of cisplatin. Immunoblotting and DNA flow cytometry analyses of one of the complexes, Pt(IV)FL2, revealed that it damages DNA, causes cell cycle arrest in S or G2/M depending on exposure time, and ultimately triggers apoptotic cell death. Fluorescence microscopic studies prove that Pt(IV)FL2 enters cells intact and undergoes reduction intracellularly. The results are best interpreted in terms of a model in which the axial fluorescein ligands are expelled through lysosomes, with the platinum(II) moiety generated in the process binding to genomic DNA, which results in cell death.

AB - Pt(IV) anticancer compounds typically operate as prodrugs that are reduced in the hypoxic environment of cancer cells, losing two axial ligands in the process to generate active Pt(II) species. Here we report the synthesis of two fluorescent Pt(IV) prodrugs of cisplatin in order to image and evaluate the Pt(IV) reduction process in simulated and real biological environments. Treatment of the complexes dissolved in PBS buffer with reducing agents typically encountered in cells, glutathione or ascorbate, afforded a 3- to 5-fold fluorescence turn-on owing to reduction and loss of their fluorescein-based axial ligands, which are quenched when bound to platinum. Both Pt(IV) conjugates displayed moderate cytotoxicity against human cancer cell lines, with IC50 values higher than that of cisplatin. Immunoblotting and DNA flow cytometry analyses of one of the complexes, Pt(IV)FL2, revealed that it damages DNA, causes cell cycle arrest in S or G2/M depending on exposure time, and ultimately triggers apoptotic cell death. Fluorescence microscopic studies prove that Pt(IV)FL2 enters cells intact and undergoes reduction intracellularly. The results are best interpreted in terms of a model in which the axial fluorescein ligands are expelled through lysosomes, with the platinum(II) moiety generated in the process binding to genomic DNA, which results in cell death.

UR - http://www.scopus.com/inward/record.url?scp=84886067517&partnerID=8YFLogxK

U2 - 10.1021/bc400281a

DO - 10.1021/bc400281a

M3 - Article

C2 - 23957697

AN - SCOPUS:84886067517

SN - 1043-1802

VL - 24

SP - 1733

EP - 1740

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

IS - 10

ER -

Synthesis and characterization of Pt(iv) fluorescein conjugates to investigate Pt(iv) intracellular transformations

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this